Oncocyte Corp (OCX)

$2.83

Market is closed - opens 7 PM, 28 May 2024

Insights on Oncocyte Corp

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 463.0K → 176.0K (in $), with an average decrease of 26.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -15.99M → -9.12M (in $), with an average increase of 75.2% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 26.1% return, outperforming this stock by 60.1%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 13.1% return, outperforming this stock by 109.8%

Performance

  • $2.71
    $2.86
    $2.83
    downward going graph

    4.24%

    Downside

    Day's Volatility :5.1%

    Upside

    0.9%

    downward going graph
  • $2.08
    $4.86
    $2.83
    downward going graph

    26.5%

    Downside

    52 Weeks Volatility :57.2%

    Upside

    41.77%

    downward going graph

Returns

PeriodOncocyte CorpSector (Health Care)Index (Russel 2000)
3 Months
-7.21%
-2.3%
0.0%
6 Months
-33.57%
10.1%
0.0%
1 Year
-34.0%
13.0%
0.0%
3 Years
-96.74%
16.4%
-19.8%

Highlights

Market Capitalization
37.9M
Book Value
$1.4
Earnings Per Share (EPS)
-5.32
PEG Ratio
0.0
Wall Street Target Price
4.06
Profit Margin
0.0%
Operating Margin TTM
-3287.5%
Return On Assets TTM
-17.75%
Return On Equity TTM
-132.29%
Revenue TTM
1.4M
Revenue Per Share TTM
0.17
Quarterly Revenue Growth YOY
-40.699999999999996%
Gross Profit TTM
188.0K
EBITDA
-20.3M
Diluted Eps TTM
-5.32
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.76
EPS Estimate Next Year
-2.1
EPS Estimate Current Quarter
-0.67
EPS Estimate Next Quarter
-0.6

Analyst Recommendation

Buy
    62%Buy
    37%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Oncocyte Corp(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
5
5
Hold
3
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 43.46%

Current $2.83
Target $4.06

Technicals Summary

Sell

Neutral

Buy

Oncocyte Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Oncocyte Corp
Oncocyte Corp
15.98%
-33.57%
-34.0%
-96.74%
-96.79%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
5.57%
7.69%
12.76%
-6.97%
109.24%
Agilent Technologies Inc.
Agilent Technologies Inc.
10.48%
20.52%
26.09%
13.08%
124.6%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
2.15%
19.16%
12.18%
25.87%
119.25%
Danaher Corp.
Danaher Corp.
6.91%
19.45%
14.03%
2.99%
101.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-1.87%
8.95%
16.27%
-5.17%
68.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Oncocyte Corp
Oncocyte Corp
NA
NA
0.0
-2.76
-1.32
-0.18
NA
1.4
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
50.01
50.01
4.75
11.05
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
36.13
36.13
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.6
37.6
2.81
21.71
0.14
0.05
0.0
119.24
Danaher Corp.
Danaher Corp.
48.05
48.05
3.13
7.61
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
31.37
31.37
1.33
11.08
0.22
0.05
NA
34.82
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Oncocyte Corp
Oncocyte Corp
Buy
$37.9M
-96.79%
NA
0.0%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$42.6B
109.24%
50.01
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$44.2B
124.6%
36.13
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$223.3B
119.25%
37.6
14.2%
Danaher Corp.
Danaher Corp.
Buy
$193.6B
101.94%
48.05
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$41.8B
68.07%
31.37
9.01%

Institutional Holdings

  • BROADWOOD CAPITAL Inc

    18.77%
  • Awm Investment Company Inc

    5.64%
  • PURA VIDA INVESTMENTS, LLC

    4.39%
  • Vanguard Group Inc

    1.85%
  • Morgan Stanley - Brokerage Accounts

    0.92%
  • Geode Capital Management, LLC

    0.46%

Company Information

oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.

Organization
Oncocyte Corp
Employees
43
CEO
Mr. Joshua Riggs
Industry
Health Technology

FAQs